US Pharma MarketingAfter rare disease flop, cash-strapped Quince finds salvation in reverse merger
After launching a hunt for strategic alternatives in January following a phase 3 rare disease flop, Quince Therapeutics has landed on an exit strategy. After launching a hunt for strategic alternatives in January following a phase 3 rare disease flop, Quince Therapeutics has landed on an exit strategy. The Bay Area biotech has announced a merger with a private pulmonary startup called Orphai Therapeutics. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research…
After launching a hunt for strategic alternatives in January following a phase 3 rare disease flop, Quince Therapeutics has landed on an exit strategy. The Bay Area biotech has announced a merger with a private pulmonary startup called Orphai Therapeutics.
Source: FierceBiotech